In a 59-year-old patient with type 2 diabetes mellitus, an A1C of 6.6%, low hemoglobin, low mean corpuscular volume and mean corpuscular hemoglobin, elevated red cell distribution width and platelet count, and an estimated glomerular filtration rate of 42 mL/min/1.73 m², what is the next step in management?

Next Step: Confirm Iron Deficiency and Investigate for Gastrointestinal Blood Loss

The immediate next step is to measure serum ferritin and transferrin saturation to confirm iron deficiency, followed by upper and lower gastrointestinal endoscopy if iron deficiency is confirmed. 1

Clinical Reasoning

This 59-year-old patient presents with microcytic anemia (low MCV and MCH) in the context of CKD stage 3b (eGFR 42) and diabetes. The elevated RDW and platelet count further support iron deficiency as the primary etiology. However, the A1C of 6.6% may be falsely low due to the microcytic anemia and increased red cell turnover, making it unreliable for assessing glycemic control in this scenario 2, 3, 4.

Immediate Diagnostic Workup

1. Confirm Iron Deficiency

• Serum ferritin: <12 μg/dL is diagnostic of iron deficiency; however, in CKD patients, absolute iron deficiency is defined as ferritin ≤100 μg/L with transferrin saturation ≤20% 1, 5
• Transferrin saturation: <20% supports iron deficiency 1, 6
• These are the most powerful tests available and should be ordered immediately 1

2. Investigate the Source of Iron Loss

Once iron deficiency is confirmed, gastrointestinal evaluation is mandatory because:

• In a 59-year-old patient (post-menopausal age range), GI blood loss is the most common cause of iron deficiency 1
• Both upper endoscopy with small bowel biopsy AND colonoscopy should be performed to exclude malignancy (gastric cancer, colon cancer) and celiac disease 1
• This is critical even in the presence of CKD, as the two conditions commonly coexist 5

Critical Pitfall: The A1C is Unreliable Here

Do not rely on the A1C of 6.6% for diabetes management decisions. The microcytic anemia with low MCV/MCH indicates shortened red blood cell lifespan, which falsely lowers A1C values 2, 3, 4. Instead:

• Use fasting glucose or continuous glucose monitoring for glycemic assessment 2, 3
• Consider serum fructosamine as an alternative glycemic marker (reflects 2-3 week average) 3
• Once the anemia is corrected, recheck A1C for accurate assessment

Management Algorithm for CKD Stage 3b with Anemia

Step 1: Laboratory Confirmation (Now)

• Serum ferritin
• Transferrin saturation
• Complete blood count with reticulocyte count 6
• Vitamin B12 and folate levels 6

Step 2: GI Investigation (If Iron Deficiency Confirmed)

• Upper endoscopy with duodenal biopsies (to exclude celiac disease) 1
• Colonoscopy or CT colonography 1
• Do not delay this evaluation—asymptomatic malignancies commonly present with iron deficiency anemia 1

Step 3: Iron Replacement

• Oral iron is first-line if tolerated (ferrous sulfate 325 mg daily) 5
• Intravenous iron if oral iron fails, is not tolerated, or if the patient requires dialysis 5
• In CKD patients not on dialysis, a trial of oral iron for 3 months is reasonable before considering IV iron 5

Step 4: Address CKD-Related Anemia (If Iron Replete)

• If anemia persists despite iron repletion, consider erythropoiesis-stimulating agents (ESAs) 7, 8
• However, correct iron deficiency first—ESAs are ineffective without adequate iron stores 6, 8

Diabetes Management Considerations with CKD Stage 3b

While addressing the anemia:

• Continue metformin at current dose if eGFR ≥45; reduce to 1000 mg daily if eGFR 30-44 9, 10
• Add an SGLT2 inhibitor (empagliflozin, canagliflozin, or dapagliflozin) for kidney and cardiovascular protection—can be initiated with eGFR >20 11, 9
• Consider a GLP-1 receptor agonist (semaglutide, liraglutide, or dulaglutide) for additional kidney and CV benefits 11, 9
• These medications should be prioritized independent of A1C given the CKD diagnosis 11, 9

Key Caveats

• The elevated platelet count may represent reactive thrombocytosis from iron deficiency or chronic inflammation—it should normalize with iron repletion 1
• Monitor potassium closely when initiating SGLT2 inhibitors or ACE inhibitors/ARBs in CKD 9
• Screen for anemia at least every 3 months in CKD patients with diabetes, as they develop anemia earlier than non-diabetic CKD patients 6
• If GI workup is negative, consider repeat evaluation if transfusion-dependent or if visible blood loss develops 1